Therapeutic protein characterization is a fundamental stage in the development and control of biopharmaceutical products. Monoclonal antibodies, recombinant proteins, enzymes, and other biological molecules have complex structures whose composition, integrity, and potential modifications must be studied using advanced analytical techniques. In this context, high-resolution mass spectrometry (HRMS) has established itself as a particularly powerful tool for the characterization of therapeutic proteins.
Its ability to perform highly accurate mass measurements and differentiate species with very similar mass-to-charge ratios makes it possible to study proteins at different levels and obtain relevant information throughout the development, characterization, and control of biotherapeutic products.
What does HRMS contribute to therapeutic protein characterization?
Unlike small molecules, proteins have considerably more complex structures. They consist of amino acid sequences that may undergo modifications during production, processing, or storage.
HRMS enables the molecular mass of a protein to be determined with high accuracy and its heterogeneity to be studied. Depending on the analytical strategy employed, the intact protein can be analyzed, subunits can be studied, or enzymatic digestion can be performed to investigate the resulting peptides.
Modern instruments can achieve resolving powers of tens or even hundreds of thousands, depending on the technology, configuration, and acquisition conditions. This capability makes it easier to differentiate closely spaced signals and obtain accurate mass data that can subsequently be compared with the theoretical values expected for the protein under study.
Therefore, high-resolution mass spectrometry can provide complementary information to other techniques used in the physicochemical characterization of therapeutic proteins.
From intact protein analysis to peptide mapping
The characterization of therapeutic proteins using HRMS can begin with intact mass analysis. This approach provides an overall view of the molecule and makes it possible to verify whether the experimental mass matches the expected mass of the protein being studied.
However, when more detailed information about its primary structure is required, peptide mapping is commonly used.
These fragments can be separated by liquid chromatography and subsequently analyzed by HRMS. The combination of LC-HRMS provides accurate masses, retention times, and fragmentation patterns that help identify peptides and confirm portions of the amino acid sequence.
In this way, peptide mapping makes it possible to move from an overall view of the protein to a more detailed analysis of its sequence and specific variants or modifications.
Identification of post-translational modifications
One of the major challenges in therapeutic protein characterization is that the same protein does not always appear as a single, completely uniform molecular species. Different variants associated with post-translational modifications (PTMs) may be present.
Glycosylation is one of the most relevant examples, particularly in proteins produced using cell-based systems. Other phenomena that can be studied include oxidation, deamidation, modifications at the termini of the chain, and certain changes associated with disulfide bonds.
Particular importance in monoclonal antibodies
Monoclonal antibodies are a good example of the complexity that analytical characterization must address.
An immunoglobulin G has an approximate mass of 150 kDa and consists of two heavy chains and two light chains connected by disulfide bonds.
HRMS applied to monoclonal antibodies can therefore be used as part of an analytical strategy to study their mass, composition, heterogeneity, and specific modifications.
Data interpretation is as important as the instrument
Therapeutic protein characterization requires analytical strategies capable of addressing the structural complexity of these molecules. High-resolution mass spectrometry offers a combination of mass accuracy, resolution, and characterization capabilities that enables proteins to be studied at different levels. These characterization strategies are consistent with the recommendations outlined in the ICH Q6B guideline, which addresses specifications and analytical procedures applicable to biotechnological and biological products.
From intact mass analysis to peptide mapping using LC-HRMS, including the identification of post-translational modifications and the characterization of monoclonal antibodies, HRMS can provide relevant information at different stages of biopharmaceutical development.
Its true value, however, does not depend solely on the capabilities of the instrument. Sample preparation, experimental design, data processing, and the correct interpretation of results are essential elements for obtaining reliable and useful characterization data.
Frequently Asked Questions
- What is therapeutic protein characterization? Therapeutic protein characterization encompasses a set of analyses designed to study the identity, composition, structure, integrity, heterogeneity, and modifications of proteins used as biological medicines.
- What is HRMS used for in therapeutic protein analysis? HRMS enables proteins to be measured with high mass accuracy and resolution. It can be used to study intact proteins, subunits, and peptides, as well as to investigate specific post-translational modifications and molecular variants.
- What is peptide mapping? Peptide mapping is an analytical strategy in which a protein is digested using a proteolytic enzyme, such as trypsin, to generate peptides that are subsequently separated and analyzed using techniques such as LC-MS or LC-HRMS.
